健脾散结方在胃癌治疗中的应用评价  

Evaluation of Jianpi Sanjie Formula(健脾散结方)in Treatment of Patients with Gastric Cancer

作　　者：刘建芳[1] 陈艳华[1] 李英[1] 张文杰 孟芹[1] 许崇德[1] LIU Jianfang;CHEN Yanhua;LI Ying;ZHANG Wenjie;MENG Qin;XU Chongde(People's Hospital of Rizhao,Rizhao 276826,Shandong,China)

机构地区：[1]日照市人民医院,山东日照276826

出　　处：《中华中医药学刊》2023年第6期251-254,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：山东省医药卫生科技发展计划项目(2016WS0329)。

摘　　要：目的分析健脾散结方联合尼妥珠单抗注射液与同步放化疗治疗胃癌的临床疗效。方法选取2018年5月—2021年5月于日照市人民医院住院治疗的60例胃癌患者,随机分为西药组(30例)和联合中药组(30例)。西药组患者采用放化疗同时进行尼妥珠单抗靶向治疗,联合中药组在上述基础上联合健脾散结方。对比两组病人的临床疗效、血液指标和有无不良反应发生。结果联合中药组的疾病控制率和有效率较西药组均显著提升;与西药组比较,联合中药组病人CEA等肿瘤标志物水平显著下降,而T淋巴细胞亚群以及NK细胞水平显著升高(P<0.05);KPS评分显著升高,且该组的不良反应较少,总发生率显著降低(P<0.05)。结论健脾散结方联合尼妥珠单抗与放化疗不仅可提高治疗胃癌的临床疗效,降低肿瘤标志物水平,调节T淋巴细胞亚群水平,且不良反应较低。Objective To analyze the clinical efficacy of Jianpi Sanjie Formula(健脾散结方)combined with Nituzumab Injec⁃tion and concurrent chemoradiotherapy in the treatment of gastric cancer.Methods A total of 60 gastric cancer patients hospital⁃ized in Rizhao People's Hospital of Shandong Province from May 2018 to May 2021 were selected and randomly divided into west⁃ern medicine group(30 cases)and combined Chinese medicine group(30 cases).Patients in the western medicine group re⁃ceived radiotherapy and chemotherapy and nituzumab targeted therapy,while patients in the combined Chinese medicine group re⁃ceived Jianpi Sanjie Formula on the above basis.The clinical efficacy,blood indexes and adverse reactions were compared be⁃tween the two groups.Results Compared with those of the western medicine group,the disease control rate and effective rate of combined Chinese medicine group were significantly improved.Compared with those of the western medicine group,CEA and oth⁃er tumor markers in the combined Chinese medicine group were significantly decreased,while T lymphocyte subsets and NK cell levels were significantly increased(P<0.05).KPS score was significantly increased,and there were fewer adverse reactions in this group,and the overall incidence was significantly decreased(P<0.05).Conclusion Jianpi Sanjie Formula combined with ni⁃tuzumab and chemoradiotherapy can improve the clinical efficacy of gastric cancer,reduce the level of tumor markers and regulate the levels of T lymphocyte subsets,with no significant increase in adverse reactions.

关 键 词：胃癌 健脾散结方 尼妥珠单抗 不良反应 生存率 

分 类 号：R273.352[医药卫生—中西医结合]